-
2
-
-
77449093512
-
Metastatic giant cell tumor of bone: Are there associated factors and best treatment modalities?
-
Viswanathan S, Jambhekar NA,. 2010. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res 468: 827-833.
-
(2010)
Clin Orthop Relat Res
, vol.468
, pp. 827-833
-
-
Viswanathan, S.1
Jambhekar, N.A.2
-
3
-
-
84868229928
-
Giant cell tumor of bone: A basic science perspective
-
Cowan RW, Singh G,. 2013. Giant cell tumor of bone: a basic science perspective. Bone 52: 238-246.
-
(2013)
Bone
, vol.52
, pp. 238-246
-
-
Cowan, R.W.1
Singh, G.2
-
4
-
-
79251470118
-
Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis
-
Conti A, Rodriguez GC, Chiechi A, et al., 2011. Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. Am J Pathol 178: 88-97.
-
(2011)
Am J Pathol
, vol.178
, pp. 88-97
-
-
Conti, A.1
Rodriguez, G.C.2
Chiechi, A.3
-
5
-
-
84877135394
-
MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone
-
Mosakhani N, Pazzaglia L, Benassi MS, et al., 2013. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. Histol Histopathol 28: 671-678.
-
(2013)
Histol Histopathol
, vol.28
, pp. 671-678
-
-
Mosakhani, N.1
Pazzaglia, L.2
Benassi, M.S.3
-
6
-
-
84864276297
-
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
-
Heymann D,. 2012. Anti-RANKL therapy for bone tumours: basic, pre-clinical and clinical evidences. J Bone Oncol. 1: 2-11.
-
(2012)
J Bone Oncol.
, vol.1
, pp. 2-11
-
-
Heymann, D.1
-
7
-
-
78650397541
-
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis
-
Lipton A, Goessl C,. 2011. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 48: 96-99.
-
(2011)
Bone
, vol.48
, pp. 96-99
-
-
Lipton, A.1
Goessl, C.2
-
8
-
-
84894931059
-
Mapping protein signal pathway interaction in sarcoma bone metastasis: Linkage between rank, metalloproteinases turnover and growth factor signaling pathways
-
Conti A, Espina V, Chiechi A, et al., 2014. Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clin Exp Metastasis 31: 15-24.
-
(2014)
Clin Exp Metastasis
, vol.31
, pp. 15-24
-
-
Conti, A.1
Espina, V.2
Chiechi, A.3
-
9
-
-
77954556987
-
Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases
-
Pazzaglia L, Conti A, Chiechi A, et al., 2010. Differential gene expression in classic giant cell tumours of bone: tenascin C as biological risk factor for local relapses and metastases. Histopathology 57: 59-72.
-
(2010)
Histopathology
, vol.57
, pp. 59-72
-
-
Pazzaglia, L.1
Conti, A.2
Chiechi, A.3
-
10
-
-
79960463418
-
Nuclear factor I/B is an oncogene in small cell lung cancer
-
Dooley AL, Winslow MM, Chiang DY, et al., 2011. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 25: 1470-1475.
-
(2011)
Genes Dev
, vol.25
, pp. 1470-1475
-
-
Dooley, A.L.1
Winslow, M.M.2
Chiang, D.Y.3
-
11
-
-
81855166112
-
NFIB is a potential target for estrogen receptor-negative breast cancers
-
Moon HG, Hwang KT, Kim JA, et al., 2011. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol 5: 538-544.
-
(2011)
Mol Oncol
, vol.5
, pp. 538-544
-
-
Moon, H.G.1
Hwang, K.T.2
Kim, J.A.3
-
12
-
-
84865603486
-
Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma
-
Buckle CH, De Leenheer E, Lawson MA, et al., 2012. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. PLoS ONE 7: e41127.
-
(2012)
PLoS ONE
, vol.7
, pp. e41127
-
-
Buckle, C.H.1
De Leenheer, E.2
Lawson, M.A.3
-
13
-
-
79952131163
-
RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma
-
Lee JA, Jung JS, Kim DH, et al., 2010. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer 56: 738-743.
-
(2010)
Pediatr Blood Cancer
, vol.56
, pp. 738-743
-
-
Lee, J.A.1
Jung, J.S.2
Kim, D.H.3
-
14
-
-
33947646303
-
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B
-
Mori K, Le Goff B, Berreur M, et al., 2007. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol. 211: 555-562.
-
(2007)
J Pathol.
, vol.211
, pp. 555-562
-
-
Mori, K.1
Le Goff, B.2
Berreur, M.3
-
15
-
-
80053185152
-
Formulated siRNAs targeting rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
-
Rousseau J, Escriou V, Lamoureux F,. 2011. Formulated siRNAs targeting rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. JBMR 26: 2452-2462.
-
(2011)
JBMR
, vol.26
, pp. 2452-2462
-
-
Rousseau, J.1
Escriou, V.2
Lamoureux, F.3
-
16
-
-
84877090907
-
Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors
-
Chiechi A, Novello C, Magagnoli G, et al., 2013. Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res 19: 2473-2485.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2473-2485
-
-
Chiechi, A.1
Novello, C.2
Magagnoli, G.3
-
17
-
-
78650304107
-
Matrix metalloproteinases as master regulators
-
Lynch CC,. 2010. Matrix metalloproteinases as master regulators. Bone 48: 44-53.
-
(2010)
Bone
, vol.48
, pp. 44-53
-
-
Lynch, C.C.1
-
18
-
-
84855392626
-
An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment
-
Thiolloy S, Edwards JR, Fingleton B, et al., 2012. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS ONE 7: e29862.
-
(2012)
PLoS ONE
, vol.7
, pp. e29862
-
-
Thiolloy, S.1
Edwards, J.R.2
Fingleton, B.3
-
19
-
-
33750738067
-
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases
-
Guise TA, Mohammad KS, Clines G, et al., 2006. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213s-6216s.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6213s-6216s
-
-
Guise, T.A.1
Mohammad, K.S.2
Clines, G.3
-
20
-
-
84862561863
-
Modern interpretation of giant cell tumor of bone: Predominantly osteoclastogenic stromal tumor
-
Yuhree K, Saqib N, Hana G, et al., 2012. Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg 4: 107-116.
-
(2012)
Clin Orthop Surg
, vol.4
, pp. 107-116
-
-
Yuhree, K.1
Saqib, N.2
Hana, G.3
-
21
-
-
18544399193
-
Identification of markers of possible prognostic value in 57 giant cell tumors of bone
-
Gamberi G, Serra M, Ragazzini P, et al., 2003. Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 10: 351-356.
-
(2003)
Oncol Rep
, vol.10
, pp. 351-356
-
-
Gamberi, G.1
Serra, M.2
Ragazzini, P.3
-
22
-
-
0035023776
-
Detection of c-fos expression in benign and malignant musculoskeletal lesions
-
Weisstein JS, Majeska RJ, Klein MJ, et al., 2001. Detection of c-fos expression in benign and malignant musculoskeletal lesions. J Orthop Res 19: 339-345.
-
(2001)
J Orthop Res
, vol.19
, pp. 339-345
-
-
Weisstein, J.S.1
Majeska, R.J.2
Klein, M.J.3
|